PROF Stock — Profound Medical Corp.

Up next

Next earnings call

Mar 4, 2027 Est · unconfirmed · in 16 wks

Q3 2026 earnings call transcript

call held Nov 5, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 12

Investor event

Stifel 2026 Healthcare Conference AI summary on its way

Nov 12

Current report 8-K Events of Nov 5

Director or officer change, or executive pay AI summary on its way

Nov 9

Current report 8-K

Management to present at Stifel 2026 Healthcare Conference

Profound Medical Corp. President Richard Fabian will present at the Stifel 2026 Healthcare Conference on Thursday, November 12, 2026 at 8:40 a.m. Eastern Time in NYC; Arun Menawat and Matthew Sobczyk will join investor meetings.

Regulation FD disclosure

2 source passages

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on Thursday, November 12, 2026 at 8:40 a.m. Eastern Time in NYC. Mr. Fabian along with Profound’s Chief Executive Officer and Chairman, Arun Menawat, and its Chief Financial Officer, Matthew Sobczyk, will also participate in one-on-one meetings with investors during the conference. Open the document at this passage

Nov 5

Earnings call

Revenue rose 86%; Cook Medical agreement expands Tulsa sales

Profound reported third-quarter revenue of $9.8 million, up 86%, and projects full-year 2026 revenue of at least $25 million. The Tulsa Pro install base reached 98 systems, and a distribution agreement with Cook Medical was signed last week.

4 source passages

For the three-month ended September 30, 2026, Profound recorded total revenue of $9.8 million, up 86% from the third quarter of 2025. we are projecting our full 2026 revenue to be at least $25 million At the end of the third quarter, our Tulsa Pro install base was 98 systems. As Rich mentioned, we added a key new distribution channel for Tulsa products under a supply and distribution agreement signed last week with Cook Medical, one of the largest privately held medical device manufacturers in the United States. Open the document at this passage

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Revenue rises 74% as nine-month net loss narrows

Profound Medical Corp. reported nine-month revenue of $17,650, up 74%, and net loss of $24,315 versus $34,395. Cash totaled $33,343 at September 30, 2026, with funding expected for at least the next 12 months.

Revenue $9.83M ▲ 85.9% Net loss $7.72M Diluted EPS -$0.21

Read from the MD&A section

7 source passages

The “Company”, the “Registrant”, “we” or “us” refer to Profound Medical Corp. For the nine months ended September 30, 2026, we recorded revenue totaling $17,650, consisting of $9,458 from the one-time sale of capital equipment and $8,192 from recurring – non-capital revenue. The increase of $7,529, or 74%, in revenue for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 was driven by higher capital sales as well as recurring revenue. Net cash used in operating activities for the nine months ended September 30, 2026 was $(24,927), primarily attributable to a net loss of $24,315 and $3,319 in net operating assets and liabilities, partially offset by $2,707 of non-cash charges. The principal use of the operating cash flows during the period related to a net loss of $34,395 and a change in net operating assets and liabilities of $(1,836) and in non-cash charges of $4,590. As of September 30, 2026, we had cash of $33,343 compared to $59,723 as of December 31, 2025. Based on our current operating plans, we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of these unaudited consolidated financial statements. Open the document at this passage

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$23.63M

Trailing 12 months

Net income (TTM)

−$32.49M

Trailing 12 months

Revenue growth YoY

+85.9%

Year over year

Operating margin

-145.1%

Trailing 12 months

P / E (TTM)

4.8

Trailing earnings · reciprocal yield 20.9%

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$28.83M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+21.4%

Year over year · more shares

Price change (1Y)

+16.9%

Trailing year

Short interest

4.3%

Latest settlement · 9.8 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

· $4.18M −$4.95M '24 Q4* ▲82.1% $2.62M −$10.72M '25 Q1 ▼1% $2.21M −$15.70M '25 Q2 ▲86.8% $5.29M −$7.98M '25 Q3 ▲43.1% $5.98M −$8.17M '25 Q4* ▲103.6% $5.34M −$7.05M '26 Q1 ▲12.3% $2.48M −$9.54M '26 Q2 LATEST ▲85.9% $9.83M −$7.72M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 5, 2026

Q3 FY26

TL;DR. Q3 revenue rose 86% to $9.8 million, gross margin improved to 78%, operating cash use fell 56% sequentially, and full-year revenue and gross-margin guidance is at least $25 million and 70% or higher; Cook Medical distribution and broader payer coverage are additional commercial opportunities. Operating expenses increased 21%, the company remained loss-making, and pipeline conversion, utilization, competition, and the lag from scaling investments remain risks.

Bullish

+ Third-quarter revenue increased 86% year over year to $9.8 million.
+ Gross margin improved to 78% from 74% in the prior-year quarter.
+ Full-year 2026 revenue is projected to be at least $25 million with gross margin of 70% or higher.
+ Cash used in operating activities fell 56% sequentially and 48% year over year.
+ Cook Medical added a new distribution channel for Tulsa products.
+ Payer engagement added approximately 10.7 million covered lives in the third quarter.

Bearish

− Operating expenses increased 21% year over year to $15.5 million.
− The company remained loss-making, with a net loss of approximately $7.7 million, or $0.21 per common share.
− The qualified sales pipeline may not convert into recognized revenue at the expected level or timing.
− Payer coverage alone does not ensure procedure utilization.
− New robotic entrants are committing substantial resources to competition.
− Scaling investment may increase expenses before contributing to revenue for several quarters.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +12%

above

Price vs 50-day avg +18%

above

RSI (14) 62

neutral

MACD trend Positive

52-week position 66%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return +23%

trailing

6-month return +10%

trailing

YTD return −6%

this year

Relative strength +9%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $7 — 200d above 50d

Institutional flow Accumulating

47 of 57 funds reported for Sep 30 · net +240.8K sh shares · +5 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.32% of shares out · ▲ +1.4% MoM · 9.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

57 holders — mid 3-yr range

Squeeze score 80

high risk · 0–100

Fundamentals

Excellent

Revenue growth +51%

Y/Y

Gross margin 71%

expanding

EPS growth +26%

Y/Y

Free cash flow $-38.4M

Balance sheet $55.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 69%

annualized · 1-yr

Max drawdown −42%

past year

ATR 6.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 6, 2026

full-year 2026

Total revenue Maintained $25M

May 7, 2026 $25M Aug 6, 2026 $25M

prior FY $16.1M midpoint +55.3% Y/Y

full year 2026

Gross margin at least 70%

Previous outlook earlier release · from the 8-K filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Gross margin · full year 2026 at least 70%

Prior guidance period ended · from the 8-K filed Oct 7, 2026

Total Revenue · third quarter 2026 $9.8M – $10M

Gross Margin · Q3-2026 at least 70%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+12% Bullish

Price vs 50-day avg

+18% Bullish

RSI (14)

62 Neutral

MACD trend

Positive Bullish

52-week position

66% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $6 › 200d $7 — 200d above 50d

Institutional flow Accumulating

47 of 57 funds reported for Sep 30 · net +240.8K sh shares · +5 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.32% of shares out · ▲ +1.4% MoM · 9.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

57 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $5 Now $7 · 66% Range high $9

vs 200-day avg +12% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
covered lives added	18.3M	Q2 2026	—
new purchase orders	$7M	Q2 2026	—
qualified commercial opportunities generated at SRS2026	160	Q2 2026	—
TULSA INDEX20 Average Procedures Annualized	40	Q2 2026	—
TULSA INDEX20 Average Procedures/Quarter	10	Q2 2026	—
TULSA INDEX20 H1-2026 Over H1-2025 Growth	39%	H1 2026	—
TULSA INDEX20 Quarterly Year-Over-Year Growth	22%	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PROF Profound Medical Corp. this stock	$271.77M	-5.7%	+50.7%	—	4.3%
ABT Abbott Laboratories	$187.95B	-13.4%	+5.7%	40.5	1.1%
MDT Medtronic plc	$131.57B	+7.1%	+8.4%	25.3	1.8%
SYK Stryker Corp	$117.88B	-11.9%	+11.2%	33.0	1.7%
BSX Boston Scientific Corp	$64.27B	-53.5%	+12.5%	18.8	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

58

% held: 44.8%
Reported: 47 of 57
Top holder: FIL Ltd

Held Float

View

Held by Funds

Fund positions

10

View

Short & Settlement

Short Interest Rising

Shares short

1.6M

Days to cover: 9.8d
Change: +22.6K sh

View

Short Volume

Short vol %

50%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

255

Value: $1.8K
As of: Oct 13, 2026

View

Off-Exchange

Off-exchange %

48.6%

Week of: Oct 5, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$16.1M

Net income (FY): $-42.6M
EPS diluted: $1.41

View

Filings

SEC Filings

Latest

8-K

Filed: Nov 12, 2026
This year: 41

View

Proposed Sales

Value

$105.5K

Shares: 13.0K
Filed: Nov 12, 2024

View

Earnings & Events

Webcasts

Last webcast

Nov 12, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
PROF	+2.9%	+23.5%	+9.6%	+12.9%	-5.7%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	+0.3%	+24.6%	+9.1%	+13.1%	-16.3%

PROF · Profound Medical Corp.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance